Ivemend
fosaprepitant
Table of contents
Overview
Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.
It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.
It contains the active substance fosaprepitant.
Authorisation details
Product details | |
---|---|
Name |
Ivemend
|
Agency product number |
EMEA/H/C/000743
|
Active substance |
fosaprepitant
|
International non-proprietary name (INN) or common name |
fosaprepitant
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
A04AD12
|
Publication details | |
---|---|
Marketing-authorisation holder |
Merck Sharp & Dohme B.V.
|
Revision |
24
|
Date of issue of marketing authorisation valid throughout the European Union |
11/01/2008
|
Contact address |
Waarderweg 39 |
Product information
25/08/2022 Ivemend - EMEA/H/C/000743 - N/0048
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiemetics and antinauseants
Therapeutic indication
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.
Ivemend 150 mg is given as part of a combination therapy.